0 items USD 0.00Search
Your search for "qyresearch 2017 2022 lenalidomide report global united states market status forecast players" gave back 1549443 results.
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also...
Catalog:
GIR
January 2023
Price: USD 3,480.00
Marginal zone lymphoma (MZL) is a group of indolent (slow growing) NHL B-cell lymphomas, which account for approximately eight percent of all NHL...
Catalog:
MRRPB5
May 2023
Price: USD 2,900.00
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease...
Catalog:
Global Markets Direct
August 2018
Price: USD 2,000.00
Market Analysis and Insights: Global Immunomodulator for Multiple Myeloma Market The global Immunomodulator for Multiple Myeloma market is projected...
Catalog:
MRRPB5
August 2023
Price: USD 4,900.00
Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Therapeutics Market The global Myelodysplastic Syndrome (MDS) Therapeutics market...
Catalog:
MRRPB5
August 2023
Price: USD 4,900.00
Highlights The global Market Research Reports and Industry Analysis market was valued at US$ million in 2022 and is anticipated to reach US$ million...
Catalog:
MRRPB5
January 2023
Price: USD 2,900.00
Publisher' newest research report, the “Market Research Reports and Industry Analysis Industry Forecast” looks at past sales and reviews total...
Catalog:
LPI
January 2023
Price: USD 3,660.00
Market Analysis and Insights: Global B-Cell Chronic Lymphocytic Leukemia Treatment Market The global B-Cell Chronic Lymphocytic Leukemia Treatment...
Catalog:
MRRPB5
August 2023
Price: USD 4,900.00
Marginal zone lymphoma (MZL) is a group of indolent (slow growing) NHL B-cell lymphomas, which account for approximately eight percent of all NHL...
Catalog:
MRRPB5
June 2023
Price: USD 4,900.00
REVLIMID® (lenalidomide), an immunomodulatory therapy used to treat people with multiple myeloma The global Revlimid market is projected to reach US...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
REVLIMID® (lenalidomide), an immunomodulatory therapy used to treat people with multiple myeloma Publisher' newest research report, the “...
Catalog:
LPI
February 2023
Price: USD 3,660.00
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also...
Catalog:
LPI
February 2023
Price: USD 3,660.00
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
REVLIMID® (lenalidomide), an immunomodulatory therapy used to treat people with multiple myeloma The global Revlimid market was valued at US$ 10350...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease...
Catalog:
Global Markets Direct
February 2018
Price: USD 2,000.00
